Delivery Hero, the German food-delivery company, has surpassed analysts' expectations by posting impressive revenue growth in the second quarter. As a result, its shares experienced a significant boost in Wednesday morning trading.
Revenue Growth Exceeds Expectations
Delivery Hero reported a revenue of 2.58 billion euros ($2.83 billion) for the quarter, representing a 16% increase compared to the previous year at constant currency. The company's gross merchandise value (GMV), a crucial indicator of sales performance, also showed growth of 8.1% at constant currency, reaching EUR11.08 billion.
Analysts React
Citi analysts had predicted lower revenue of EUR2.49 billion and a GMV figure of EUR11.01 billion. Consequently, Delivery Hero's better-than-expected results garnered positive attention from analysts. Jefferies analysts expressed their satisfaction with the company's profitability progress in a research note.
Strong Projections for the Future
Delivery Hero now foresees revenue growth of approximately 15% at constant currency for the full year, surpassing its previous forecast of about 10%. Additionally, the company maintains its expectations for GMV growth of 5% to 7% and an adjusted Ebitda to GMV margin of over 0.5%.
Delivery Hero's thriving performance in the second quarter has instilled confidence in investors and analysts alike. The company remains dedicated to sustaining robust growth and profitability.
Nikon Q1 Net Profit Drops 78%, Shares Decline
Related Articles
McDonald's Set to Open 10,000 New Restaurants in Rapid Expansion
McDonald's plans to open 10,000 new restaurants and attract 250 million users to its loyalty program. The company aims to operate 50,000 stores by 2027.
Asia-Pacific Stocks Experience Declines
Stocks in the Asia-Pacific region, including Hong Kong, Japan, China, Singapore, South Korea, and Australia, experienced declines. Semiconductors decrease in va...
PepsiCo: Weathering the Storm and Looking to the Future
PepsiCo has faced challenges but remains confident in its outlook, with a competitive yield and consistent dividend growth. Weight-loss drugs are unlikely to si...